Risk Factors Analysis of Thrombocytopenia in Patients with Severe Pulmonary Infection Treated with Cefoperazone Sulbactam
Objective:To investigate the risk factors of thrombocytopenia in patients with severe pulmonary infection after treatment with cefoperazone and sulbactam.Methods:Clinical data of 179 patients with severe pulmonary infection admitted to our hospital from December 2021 to December 2023 were retrospectively analyzed.All of them were treated with cefoperazone and sulbactam anti-infection regimen.They were divided into occurrence group and non-occurrence group according to whether thrombocytopenia occurred.The basic data of all patients,including age,gender,duration of medication,combination of hypertension,diabetes,chronic kidney disease,liver disease,albumin level,and combination of drugs were collected.Logistic regression analysis of risk factors for thrombocytopenia in patients with severe pulmonary infection treated with cefoperazone sulbactam.Results:Among 179 patients,a total of 16 patients developed thrombocytopenia,with an incidence rate of 8.94%.There were statistically significant differences in age,medication duration,comorbidities of chronic kidney disease,comorbidities of liver disease,and types of combination therapy between patients with concurrent thrombocytopenia and those without concurrent thrombocytopenia(P＜0.05).The results of Logistic regression analysis showed that age≥80 years(OR=5.150),medication duration≥10 days(OR=9.793),concomitant chronic kidney disease(OR=6.095),concomitant liver disease(OR=6.765),and≥5 types of combination therapy(OR=1.025)were independent risk factors for thrombocytopenia in patients with severe pulmonary infection after treatment with cephalospora sulbactam(P＜0.05 and OR＞1).Conclusion:Thrombocytopenia in patients with severe pulmonary infection after treatment with cefoperazone and sulbactam is associated with age≥80 years old,duration of treatment≥10 days,combination of chronic kidney disease,combination of liver disease,and combination of drug types≥5 kinds,which should be paid great attention to,optimize the treatment plan,and reduce the occurrence of thrombocytopenia.
Severe pulmonary infectionCefoperazone sulbactamThrombocytopeniaRisk factors
万方数据
维普
